Download PDF
Exp Clin Endocrinol Diabetes 2016; 124(07): 437-439
DOI: 10.1055/s-0042-106081
Mini-Review
© Georg Thieme Verlag KG Stuttgart · New York

Dicarbonyl Stress Mimics Diabetic Neurovascular Damage in the Retina

M. Kolibabka   *
1   5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
P. Friedrichs   *
1   5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
N. Dietrich   *
1   5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
T. Fleming
2   Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
A. Schlotterer
1   5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
H.-P. Hammes
1   5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
› Author Affiliations
Further Information

Publication History

received 29 March 2016
first decision 06 April 2016

accepted 06 April 2016

Publication Date:
24 May 2016 (online)

Also available at
    Permissions and Reprints

Abstract

The net effect of euglycemic treatment is grossly overestimated in diabetes mellitus and retinopathy, similar to what is observed in diabetic individuals, is found in the absence of chronic hyperglycemia. Explanations of this clinical paradox include the excess generation of reactive intermediates of metabolism. Excess formation or impaired detoxification of reactive intermediates can also result in multiple posttranslational modifications with a wide range of cellular dysfunctions. The multicellular neurovascular unit represents the response element of the retina which is crucial for the development of diabetic retinopathy. Current evidence suggests that increased reactive intermediates in the retina induce (micro-)glial activation, neurodegeneration and vasoregression similar to alterations found in the diabetic retina. Reactive metabolites can be lowered by metabolic signal blockade, by an activation of detoxification pathways and by quenching. The translation of these novel findings into treatment of patients with complications is important to reduce individual suffering and financial burden for societies.

Quick Summary:Increased levels of reactive intermediates, independent of blood glucose levels, are linked to damage of the neurovascular unit of the diabetic retina.

Key words

reactive metabolites - diabetic complications - diabetic retinopathy

* equally contributed


 

  • References

  • 1 Bohn B, Rosenbauer J, Icks A et al. Regional disparities in diabetes care for pediatric patients with type 1 diabetes. A cross-sectional DPV multicenter analysis of 24 928 German children and adolescents. Experimental and clinical endocrinology & diabetes: official journal. German Society of Endocrinology [and] German Diabetes Association 2016; 124: 111-119 DOI: 10.1055/s-0042-101159.
    PubMedGoogle Scholar
  • 2 Neu A, Beyer P, Burger-Busing J et al. Diagnosis, therapy and control of diabetes mellitus in children and adolescents. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 2014; 122: 425-434 DOI: 10.1055/s-0034-1366384.
    PubMedGoogle Scholar
  • 3 Koster I, Huppertz E, Hauner H et al. Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 2014; 122: 510-516 DOI: 10.1055/s-0034-1375675.
    PubMedGoogle Scholar
  • 4 Damato EM, Murray N, Szetu J et al. Sight-threatening diabetic retinopathy at presentation to screening services in Fiji. Ophthalmic epidemiology 2014; 21: 318-326 DOI: 10.3109/09286586.2014.949781.
    CrossrefPubMedGoogle Scholar
  • 5 Raum P, Lamparter J, Ponto KA et al. Prevalence and cardiovascular associations of diabetic retinopathy and maculopathy: results from the gutenberg health study. PLoS One 2015; 10: e0127188 DOI: 10.1371/journal.pone.0127188.
    CrossrefPubMedGoogle Scholar
  • 6 Authors/Task Force M . Ryden L, Grant PJ et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European heart journal 2013; 34: 3035-3087 DOI: 10.1093/eurheartj/eht108.
    CrossrefPubMedGoogle Scholar
  • 7 Stitt AW, Curtis TM, Chen M et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res 2015; DOI: 10.1016/j.preteyeres.2015.08.001.
    PubMedGoogle Scholar
  • 8 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Nationale VersorgungsLeitlinie Prävention und Therapie von Netzhautkomplikationen bei Diabetes – Langfassung, 2. Auflage. Version 1.2015. Available from: www.netzhautkomplikationen.versorgungsleitlinien.de [cited: 05.04.2016]; DOI: 10.6101/AZQ/000244
    PubMed
  • 9 Fullerton B, Jeitler K, Seitz M et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. The Cochrane database of systematic reviews 2014; 2: CD009122 DOI: 10.1002/14651858.CD009122.pub2.
    PubMedGoogle Scholar
  • 10 Hirsch IB, Brownlee M. Beyond hemoglobin A1c – need for additional markers of risk for diabetic microvascular complications. Jama 2010; 2291-2292 DOI: 10.1001/jama.2010.785.
    PubMedGoogle Scholar
  • 11 Lamparter J, Raum P, Pfeiffer N et al. Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study. Journal of diabetes and its complications 2014; 28: 482-487 DOI: 10.1016/j.jdiacomp.2014.02.008.
    CrossrefPubMedGoogle Scholar
  • 12 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625 DOI: 54/6/1615. [pii]
    CrossrefPubMedGoogle Scholar
  • 13 Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiological reviews 2013; 93: 137-188 DOI: 10.1152/physrev.00045.2011.
    CrossrefPubMedGoogle Scholar
  • 14 Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circulation research 2010; 107: 1058-1070 DOI: 10.1161/circresaha.110.223545.
    CrossrefPubMedGoogle Scholar
  • 15 Hammes HP, Alt A, Niwa T et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999; 42: 728-736 DOI: 10.1007/s001250051221.
    CrossrefPubMedGoogle Scholar
  • 16 Tikellis C, Pickering RJ, Tsorotes D et al. Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes 2014; 63: 3915-3925 DOI: 10.2337/db13-0932.
    CrossrefPubMedGoogle Scholar
  • 17 Feng Y, Busch S, Gretz N et al. Crosstalk in the retinal neurovascular unit – lessons for the diabetic retina. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 2012; 120: 199-201 DOI: 10.1055/s-0032-1304571.
    PubMedGoogle Scholar
  • 18 Wang J, Lin J, Schlotterer A et al. CD74 indicates microglial activation in experimental diabetic retinopathy and exogenous methylglyoxal mimics the response in normoglycemic retina. Acta diabetologica 2014; 51: 813-821 DOI: 10.1007/s00592-014-0616-9.
    CrossrefPubMedGoogle Scholar
  • 19 Rabbani N, Thornalley PJ. Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochemical and biophysical research communications 2015; 458: 221-226 DOI: 10.1016/j.bbrc.2015.01.140.
    CrossrefPubMedGoogle Scholar
  • 20 Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature medicine 2003; 9: 294-299 DOI: 10.1038/nm834.
    CrossrefPubMedGoogle Scholar
  • 21 Berner AK, Brouwers O, Pringle R et al. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012; 55: 845-854 DOI: 10.1007/s00125-011-2393-0.
    CrossrefPubMedGoogle Scholar
  • 22 McVicar CM, Ward M, Colhoun LM et al. Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetologia 2015; 58: 1129-1137 DOI: 10.1007/s00125-015-3523-x.
    CrossrefPubMedGoogle Scholar